-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology Luminex Platform: Features and Advantages in Detail
Author:
InnoModels
Release time:
2024-07-01
In the field of pharmaceutical R&D, high-throughput, efficient and accurate experimental platforms play a crucial role in the discovery and development of new drugs. InnoModels Biotechnology Luminex platform is an innovative experimental tool born to meet this need. Its features and advantages in drug discovery and development are remarkable, providing powerful technical support for researchers.
Features:
1. High-throughput processing capability: The Luminex platform is known for its highly efficient multi-factor detection capability, which is capable of detecting up to 50 different biomarkers simultaneously in one experiment. This high-throughput processing greatly shortens the experimental cycle and improves experimental efficiency.
2. High flexibility: The platform supports a wide range of sample types, such as plasma, urine, cerebrospinal fluid, etc., and can be used in a variety of research scenarios, including drug safety assessment, disease diagnosis, and immunophenotyping.
3. High sensitivity and accuracy: The Luminex platform utilizes advanced bioassay technology to provide extremely high sensitivity and accuracy. This enables researchers to more accurately assess the mechanism of action and biosafety of drugs.
4. Easy to operate and automate: The platform is simple to operate, easy to start, and supports automated operation, which greatly reduces the work intensity of researchers and improves the repeatability and accuracy of experiments.

Advantages:
1. Reduced R&D costs: Through high-throughput processing and automated operation, the Luminex platform significantly reduces the cost of drug development. Researchers can simultaneously test multiple biomarkers in one experiment, thus reducing the number of experiments and sample consumption.
2. Improved R&D efficiency: The platform's efficient processing capabilities enable researchers to obtain results faster, shortening the drug discovery cycle. In addition, the high degree of automation reduces human error and improves the accuracy of experiments.
3. Enhanced R&D capabilities: The versatility and flexibility of the Luminex platform enables researchers to gain a more comprehensive understanding of the mechanism of action and biosafety of drugs. This helps researchers discover new drug targets and provides new directions for new drug development.
4. Promote immunology research: The platform has a wide range of applications in immunology research. By detecting a variety of immune-related biomarkers, researchers can gain a deeper understanding of the function of the immune system and the mechanism of disease occurrence, which will provide strong support for the development of immunotherapeutic drugs.
In conclusion, the Luminex platform of InnoModels Biotechnology is playing an increasingly important role in the field of drug discovery and development with its features and advantages such as high throughput, high sensitivity, high accuracy, easy operation and automation. The platform not only reduces the R&D cost and improves the R&D efficiency, but also promotes the in-depth development of immunology research and provides strong technical support for new drug development.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd